Claudin18.2 targeting CAR-T cell therapy (Essen Biotech)

N/A

Report date: 2025/07/23 11:38:25

Base Information

Drug NameClaudin18.2 targeting CAR-T cell therapy (Essen Biotech)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionClaudin 18 protein modulators

TargetsClaudin-18 splice variant 2

Therapy Area/IndicationsPancreatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaPhase 2 Clinical

Originator CompaniesEssen Biotech

China Registration ClassN/A

Develop Information

Active CompaniesEssen Biotech

Inactive CompaniesN/A

Active IndicationsPancreatic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A